
    
      The purpose of this study is to evaluate MR-guided cryoablation of biopsy proven prostate
      tumors using the Galil MRI-compatible cryoablation system. The system has been approved by
      the United States Food and Drug Administration (FDA) for soft tissue ablation and has been
      utilized successfully at Mayo. All procedures will be performed according to approved
      indications. the investigators wish to monitor the technique and collect data at the
      participants follow-up visits.

      The study only collects data about the MRI-guided cryoablation procedure the participants
      doctor(s) would normally perform in order to treat the participants focal prostate cancer and
      to evaluate the participants condition after there treatment is performed. The participants
      doctor will advise the participants when the participants should return for follow-up visits.
      These visits will be according to the participants doctor's standard of care; usually return
      visits are at 3-6months, 12 months, 24 months, 36 months, 48 months and 60 months after the
      procedure, although the participants doctor may ask that the participants return for more
      frequent visits.
    
  